The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice

Mediterranean Journal of Rheumatology

ARTICLE

Evrydiki Kravvariti¹  George D. Kitas²  Petros P. Sfikakis¹ 

[1] First Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, National & Kapodistrian University of Athens Medical School;Clinical Research Unit, Dudley Group NHS Foundation Trust;Arthritis Research UK Centre for Epidemiology, University of Manchester

关键词: Nocebo;    nocebo effect;    biosimilars;    rheumatoid arthritis;    drug discontinuation;   

DOI  :  10.31138/mjr.30.1.63

学科分类：社会科学、人文和艺术（综合）

来源: PCO Convin S.A.

【 摘 要 】

The management of patients with rheumatic diseases in routine practice is guided by established measures of response to treatment with a target of low disease activity or remission. In addition to objective clinical data, subjective patient-reported outcomes (such as the number of tender joints or the patient’s perception of their general health status) are taken into account when assessing efficacy and tolerability of disease-modifying anti-rheumatic drugs (DMARDs), including bio-originator and biosimilar biologic DMARDs. A growing body of evidence suggests that the impact of DMARDs on subjective symptoms in rheumatic diseases is significantly affected by the patients’ expectations of treatment effects, either favorably when pre-existing expectations are positive (placebo effect), or detrimentally when pre-existing expectations are negative (nocebo effect).

【 授权许可】

CC BY-NC